Understanding Breast Density: A Key Factor in Breast Cancer Risk and Detection

Breast density refers to the proportion of fibroglandular and connective tissue compared to fatty tissue in the breast, as seen on a mammogram. Fibroglandular tissue appears white, while fatty tissue is dark. The Breast Imaging Reporting and Data System (BI-RADS), developed by the American College of Radiology, categorizes density into four levels: A (almost entirely fatty), B (scattered areas of fibroglandular density), C (heterogeneously dense), and D (extremely dense). Women with categories C and D—about 40-50% in many populations—face challenges because dense tissue can mask tumors, reducing mammography sensitivity from around 87% in fatty breasts to as low as 62% in extremely dense ones. Moreover, high breast density independently increases breast cancer risk by 4-6 times compared to fatty breasts.

In Aotearoa New Zealand, where breast cancer is the most common cancer among women, affecting one in nine over their lifetime, understanding density is crucial. Incidence rates are among the world's highest at 93 per 100,000, with Māori women 21% more likely to be diagnosed and 33% more likely to die, while Pacific women face 52% higher mortality risk. These disparities underscore the need for equitable screening strategies.

BreastScreen Aotearoa: New Zealand's National Screening Programme

BreastScreen Aotearoa (BSA), launched in 1998, offers free biennial mammograms to women aged 45-69, recently expanding to 74 by October 2025. It uses double-reading by radiologists for high accuracy, detecting cancers early when treatment is most effective. Participation rates hover around 70%, but lower among Māori (62%) and Pacific women (55%), contributing to inequities. BSA screens over 200,000 women annually, identifying about 1,000 cancers yearly. However, interval cancers—those missed between screens—are more aggressive, highlighting limitations in standard mammography.

Currently, BSA does not measure or report breast density to participants, unlike private providers where women can request it. This gap leaves many unaware of their risk or masking potential, prompting calls for change from advocacy groups like Breast Cancer Aotearoa Coalition (BCAC).

Current Policy on Breast Density Reporting in New Zealand

Health New Zealand – Te Whatu Ora's May 2025 technical review confirmed BSA's stance: no routine density notification due to insufficient evidence for supplemental screening in average-risk women, potential harms like anxiety and overdiagnosis, and resource constraints. High-risk women (e.g., family history, BRCA mutations) are referred for MRI or ultrasound outside BSA. The review noted workforce shortages, limited MRI access (only 20 units nationwide), and infrastructure needs.

Yet, the Royal Australia and New Zealand College of Radiologists (RANZCR) updated its position in September 2024, advocating mandatory density reporting in screening and diagnostics to inform personalized risk discussions. Private clinics like Pacific Radiology and Allevia Radiology already offer density-informed supplemental ultrasound or tomosynthesis for dense breasts, but this creates a two-tier system.

The Landmark NZMJ Viewpoint: Policy Imperatives and Research Gaps

Published March 13, 2026, in the New Zealand Medical Journal (NZMJ), the viewpoint by Avisak Bhattacharjee from University of Otago and Fay Sowerby from BCAC argues for urgent policy action. It contrasts NZ's non-notification with mandates in the US (FDA since 2023), Canada (Dense Breasts Canada), and Australia (state-level letters/fact sheets). The European Society of Breast Imaging (EUSOBI) also recommends informing women aged 50-70 with extremely dense breasts for MRI every 2-4 years.

Key evidence: Supplemental MRI detects 3x more cancers in dense breasts (DENSE trial), ultrasound adds detection but increases recalls. AI tools offer reproducible BI-RADS scoring, reducing radiologist workload by 38% and spotting missed interval cancers. The authors highlight ethical issues: withholding density info undermines autonomy, trust, and equity, especially for Māori/Pacific women with higher interval cancer rates.

International Lessons for New Zealand

Australia's BreastScreen varies: Western Australia sends letters for C/D density with GP referrals; South Australia notifies all with factsheets. US letters often exceed grade 8 readability, causing confusion; studies show no anxiety rise from notification, but misunderstanding does. Canadian and Australian pilots emphasize clear communication and GP involvement.

These models suggest NZ could pilot density letters with education, GP notifications, and culturally tailored resources (e.g., te reo Māori). For more on global radiology careers, explore higher ed jobs in medical imaging.

Read the full NZMJ viewpoint | RANZCR Position Statement

Equity Challenges: Impact on Māori and Pacific Women

Māori women develop breast cancer younger (average 58 vs 62 for European), with 30% fewer early detections and higher late-stage presentations. Pacific women face similar barriers: lower screening uptake, language/cultural hurdles. High density is more prevalent in younger/Asian women, compounding risks. Without density awareness, personalized screening (e.g., annual tomosynthesis) remains inaccessible, perpetuating disparities.

BCAC advocates risk-stratified screening incorporating density, genetics, and lifestyle. University research, like Otago's, emphasizes tikanga Māori in communication.

Research Priorities Outlined in the NZMJ Paper

• Prevalence of density categories in NZ women, stratified by ethnicity/age.
• Women's knowledge, attitudes, informational needs—culturally responsive surveys for Māori/Pacific.
• Impact of non-notification: anxiety, trust, decision-making using validated tools like State-Trait Anxiety Inventory.
• GP readiness: understanding, management pathways for dense breasts.
• Optimal communication: readability (grade 7-8), formats (letters, apps), AI integration pilots.
• Supplemental screening trials: cost-effectiveness of MRI/ultrasound in NZ context.

These priorities align with Te Whatu Ora's review, urging funded studies at universities like Otago and Auckland. Check NZ academic opportunities for related roles.

The Role of AI and Technology in Advancing Detection

AI excels in density assessment: consistent BI-RADS, 38% workload reduction, detects 1/3 missed interval cancers. BSA's ongoing AI study could standardize reporting. Emerging tools like Volpara automate density/volumetric analysis, aiding risk models (e.g., Tyrer-Cuzick). Integrating AI addresses radiologist shortages (NZ has ~300, demand rising).

Implementation Challenges and Solutions

Barriers: MRI backlog (waits 6+ months), 20 units for 5M population; training needs; costs (~NZ$500/MRI). Solutions: phased rollout (high-risk first), public-private partnerships, AI triage. Communication pilots like South Australia's reduced anxiety via clear factsheets. Governance: assign Te Whatu Ora leadership with timelines (e.g., 2027 rollout).

For career advice in radiology research, visit higher ed career advice.

Photo by Mariia Horobets on Unsplash

Future Outlook: Towards Equitable, Personalized Screening

The NZMJ viewpoint signals momentum: with BSA expansion and AI trials, 2026-2028 could see policy shift. Benefits: earlier detection (reducing 20% interval cancers), empowered women, closed equity gaps. Actionable steps: women ask GPs about density; support BCAC advocacy; researchers prioritize local trials. As NZ aligns with global standards, breast cancer outcomes improve—potentially saving 100+ lives yearly.

Explore rate my professor for Otago radiology experts, higher ed jobs in oncology, or university jobs in NZ health research. Share your thoughts below.